Eurofins cuts 2026 growth outlook for Eurofins stock
Published on 10/21/2026 at 10:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGrowth outlook shifts in 2026
- Eurofins reported EUR 5.614 billion in nine-month revenue, up 3.70 percent, on October 21, 2026.
- The company kept its 24.00 percent adjusted EBITDA margin objective for fiscal year 2027.
- Eurofins stock last stood at EUR 79.50 on Tradegate on October 20, 2026.
Eurofins (FR0014000MR3) reported EUR 5.614 billion in revenue for the first nine months of 2026, an increase of 3.70 percent from the same period a year earlier. In its trading update dated October 21, 2026, Eurofins lowered its full-year 2026 organic growth outlook while keeping its profitability and cash-flow objectives.
Growth slows while revenue rises
The company said organic growth reached 3.50 percent in the third quarter of 2026, compared with 3.00 percent in the second quarter and 2.50 percent in the first quarter. The sequential improvement did not prevent management from expecting full-year organic growth below its previous mid-single-digit objective, as some clinical programs are not expected to restart in 2026.
Eurofins also reported EUR 1.913 billion in third-quarter revenue, up from EUR 1.803 billion a year earlier. Acquisitions contributed to the expansion, with 22 deals completed during the first nine months and 2025 revenue of more than EUR 210 million attached to those transactions, excluding the Element business.
What does the outlook mean for margins?
The margin target remains the key counterweight to the softer growth outlook. Eurofins expects its adjusted EBITDA margin to improve in fiscal year 2026 from 22.50 percent in fiscal year 2025 and retained its 24.00 percent objective for fiscal year 2027, according to Eurofins.
Three dates show the strategy
On July 23, 2026, Eurofins published its first-half 2026 results and reported 130 basis points of adjusted EBITDA margin expansion, according to Eurofins. On October 1, 2026, it completed the USD 400 million acquisition of Element's North American Life Sciences Testing Services business. On October 21, 2026, the nine-month update showed EUR 5.614 billion in revenue and a 3.70 percent increase, with the current event described by Eurofins.
Investor dates follow the update
Eurofins will host an investor event in Amersfoort on October 23, 2026, followed by an event in Toronto on November 11, 2026. Both dates are listed on the company's investor-relations page, Eurofins.
Tradegate price remains the market reference
The last available euro price stood at EUR 79.50 on Tradegate on October 20, 2026 at 8:30 p.m. CEST. Eurofins stock is listed on Euronext Paris, and its market capitalization was EUR 13.9 billion as of October 21, 2026; the 52-week range was EUR 54.86 to EUR 80.44.
The further course of trading is shown by the continuously updated real-time quote of Eurofins stock.
Eurofins stock facts
- Company: Eurofins Scientific SE
- ISIN: FR0014000MR3
- Ticker: ESF0
- Primary exchange: Euronext Paris
- Substitute price Tradegate as of October 20, 2026, 8:30 p.m. CEST: EUR 79.50
- Market capitalization: EUR 13.9 billion (as of October 21, 2026)
- 52-week range: EUR 54.86-80.44 (as of October 21, 2026)
- Sector / Industry: Biotechnology and medical research
- Index membership: Euronext 100
Market context: Market report CAC 40.
